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split ends, a new component of the Drosophila EGF receptor
pathway, regulates development of midline glial cells
Fangli Chen and Ilaria Rebay
Signaling by DER, the Drosophila epidermal growth
factor receptor tyrosine kinase (RTK), is essential for
proper migration and survival of midline glial cells
(MGCs) in the embryonic central nervous system (CNS)
[1–4]. We recently isolated a gene called split ends
(spen) in a screen designed to identify new components
of the RTK/Ras pathway [5]. Drosophila Spen and its
orthologs are characterized by a distinct set of RNA
recognition motifs (RRMs) and a SPOC domain, a
highly conserved carboxy-terminal domain of unknown
function [5–7]. To investigate spen function in the
context of RTK signaling, we examined the
consequences of spen loss-of-function mutations on
embryonic CNS development. We found that spen was
required for normal migration and survival of MGCs and
that embryos lacking spen had CNS defects strikingly
reminiscent of those seen in mutants of several known
components of the DER signaling pathway. In addition,
spen interacted synergistically with the RTK effector
pointed. Using MGC-targeted expression, we found that
increased Ras signaling rescued the lethality
associated with expression of a dominant-negative
spen transgene. Therefore, spen encodes a positively
acting component of the DER/Ras signaling pathway.
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Results and discussion
To examine the consequences of complete loss of spen
function, we generated spen germline clones using the
ovoD-FLP/FRT system [8]. Embryos lacking both mater-
nal and zygotic spen will be referred to as ‘spen mutants’.
These mutants exhibited moderate defects in CNS mor-
phology, as visualized by anti-Elav antibody, a pan-neu-
ronal marker. In stage 16 spen mutant embryos, the space
separating the two longitudinal halves of the CNS was
reduced compared with the wild type and, in some 
segments, the two sides were completely collapsed across
Figure 1
The spen gene is required for migration and survival of MGCs.
(a,b) CNS morphology in stage 16 (a) wild-type (WT) and
(b) spenAH393 mutant embryos, as revealed by immunostaining with
anti-Elav antibody. The mutant shows mild collapse of the CNS.
(c) Stage 13 embryo double labeled with antibodies against Spen and
β-galactosidase. The embryo carries an enhancer trap (line AA142)
that shows specific staining in the MGCs. Spen (red) was most
strongly expressed in the MGCs, which are marked by the lacZ
expression (green). Overlapping expression appears as yellow.
Anterior is to the left in (a–c). (d,e) Dissected CNS from stage 16
(d) wild-type and (e) spenAH393 embryos immunostained with MGC-
specific anti-Slit antibody. The brackets highlight the space between
the anterior and posterior commissure (AC and PC) bundles. Anterior
is to the top. In (d), the MGCs have wrapped around and physically
separate the AC and PC bundles. In (e), the number of Slit-positive
cells is reduced and the remaining MGCs do not ensheathe the
commissures, leading to reduced separation between the AC and PC
bundles. (f–m) Anti-β-galactosidase antibody staining of the nuclear
P[slit 1.0 lacZ] enhancer trap. In (f) the wild type, there are three
MGCs per segment (arrows). In (g) spen mutants, many segments had
only one remaining MGC. When multiple MGCs were present, they
were positioned abnormally, reflecting the earlier migration defect.
(h,j,l) Wild type. (i,k,m) spenAH393. The MGCs appeared normal at
(h,i) stage 12. At (j,k) stage 13, the migration defect was apparent and,
by (l,m) stage 17, fewer MGCs persisted in spen mutants relative to
wild type. Embryos are oriented with anterior to the left in (h–m).
See Supplementary material for further methodological detail.
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the midline (Figure 1a,b). Because of this collapse, the
midline neurons were difficult to detect; however, label-
ing with the antibody 22C10 revealed that the ventral
midline neurons were present and had no obvious defects
in their projections (data not shown). Because such col-
lapsed CNS phenotypes might be indicative of defects in
the midline, spen mutant embryos were examined for
expression of the MGC-specific marker Slit [9]. Initial
determination of the MGCs appeared normal in spen
mutants (Table 1 and Figure 1h,i). The first detectable
defects occurred at late stage 12/early stage 13 when the
MGCs normally initiate their migration. In the wild type,
the glial cells migrate in a tightly packed configuration
along the dorsal surface of the ventral nerve cord, whereas
in spen mutants, the glia migrated aberrantly and became
spread out in a more diffuse pattern (Figure 1j,k). The
results of our analyses differ from a recent report that
excessive numbers of MGCs are initially specified in spen
mutants [7] (see Supplementary material for additional
discussion). Using the Slit–lacZ nuclear enhancer trap
marker to count the MGCs, we detected comparable
numbers of MGCs in the wild type and in spen mutants up
until stage 13, and a reduction in MGC number in spen
mutants beginning at stage 14 (Table 1). Thus, in our spen
mutants, which appear to be genetic and protein nulls,
normal numbers of MGCs are initially specified, a pheno-
type consistent with what has been reported for other
DER pathway mutants [4]. 
By stage 16, in a wild-type embryo, the Slit-positive MGCs
have migrated and elongated to ensheathe the anterior
commissure (AC) and posterior commissure (PC) axons,
thereby maintaining proper separation and bundling
(Figure 1d). In similarly staged spen mutant embryos, the
MGCs had not properly migrated or wrapped themselves
around the commissure bundles (Figure 1e). In addition,
while apoptosis reduces the number of MGCs in wild type
embryos from ~8 per segment at stage 13 down to only ~3
per segment by stage 16–17, in spen mutants this reduction
was even more drastic, leaving only 1–2 MGCs per
segment (Table 1 and Figure 1f,g,l,m). Thus, in spen
mutants, although initiation of MGC differentiation
appears normal, the later aspects of glial development,
including migration, wrapping, and survival or mainte-
nance of the MGC fate, are defective. To confirm that
Spen was expressed in the MGCs at stage 13 when its
function is required, embryos carrying the MGC-specific
enhancer trap line AA142, were double labeled with anti-β-
galactosidase and anti-Spen antibodies (Figure 1c). The
highest level of Spen expression was seen in the MGCs. 
Because defects in glial cell development are likely to
perturb organization of the CNS, spen mutant embryos
were labeled with the antibody BP102, which highlights
all axon tracts in the CNS. As predicted, the AC and PC
axon bundles were not properly organized or separated
and, in some segments, were completely fused
(Figure 2a,b). In addition, the two longitudinal connec-
tives appeared closer together than normal and were occa-
sionally fully collapsed across the midline (Figure 2a,b).
Staining with the anti-Fasciclin II (FasII) antibody, which
highlights a distinct set of three axon bundles in each lon-
gitudinal branch, further clarified this phenotype. These
longitudinal axon tracts never cross the midline in a wild-
type embryo (Figure 2c). In contrast, the FasII-positive
axons crossed and recrossed the midline in spen mutants,
producing a fragmented and disorganized longitudinal
axonal array (Figure 2d). 
In Drosophila, the genes rhomboid, Star, pointed and spitz,
all positively acting components of the DER pathway,
share a characteristic CNS phenotype similar to that of
spen mutants [1]. Specifically, whereas the proper number
of MGCs are initially specified, they later migrate abnor-
mally and eventually degenerate and die [3,4]. The phe-
notypic similarities between spen and the DER pathway
genes, as well as our isolation of spen as an enhancer of an
activated yan allele, are consistent with the hypothesis that
spen may be a positively acting factor in the DER/Ras 
signaling pathway. To explore this possibility, we first
determined whether spen and the RTK pathway effector
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Figure 2
The spen mutants exhibit severe axon guidance defects. Dissected
CNS from stage 16 embryos oriented with anterior to the top. 
(a,b) Immunostaining with antibody BP102, or with (c–e) anti-FasII
antibody. (a,c) Wild type embryos. (b,d) The spenAH393 mutants had
collapsed commissures, reduced separation between the two
longitudinal branches, and gaps and inappropriate crossings of the
midline by the longitudinal axons. (e) In the spen/+; pnt/+ embryo,
inappropriate crossing of the midline by the longitudinal axons is
highlighted by the arrow. BP102 (obtained from the Developmental
Studies Hybridoma Bank) was used at a 1:10 dilution, and the anti-
FasII monoclonal antibody 1D41H9 at 1:10.
(a)
WT
(b)
spen
(c)
WT
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Table 1
The spen gene is required for midline glial cell survival.
Wild type spenAH393
Stage 13 8.0 ± 0.9 (18) 8.1 ± 0.4 (24)
Stage 15 4.8 ± 0.1 (24) 3.5 ± 0.3 (24)
Stage 17 3.1 ± 0.2 (44) 1.9 ± 0.1 (39)
The number of segments counted (n) is given in parentheses.
pointed (pnt) interact synergistically in the midline. The
expectation is that a reduction in activity of a proven posi-
tive effector of the DER pathway, such as pnt, should
dominantly enhance the spen phenotype. Embryos lacking
maternal spen can be partially rescued by zygotic spen
expression from a paternally inherited wild-type allele (we
refer to this genotype as spen/+). Stage 15–17 spen/+
embryos appeared phenotypically wild type, with only
~4% of the embryos exhibiting CNS defects (Table 2).
Embryos heterozygous for a pnt loss-of-function mutation
(pnt/+) have no apparent dominant defects (Table 2).
Reducing the pnt dosage in the spen/+ background
increased the frequency of axonal defects to ~25%
(Table 2). The predominant phenotype was reduced sepa-
ration between the two longitudinal axon pathways and a
single inappropriate crossing of the midline by one of the
FasII-positive axon tracts (Figure 2e). This dose-sensitive
interaction between pnt and spen strongly supports a role
for spen as either a positively acting component of the
DER pathway or as a component of a parallel pathway
synergizing with DER during MGC development.
To investigate further the connection between spen and
DER/Ras signaling in the MGCs, we generated a putative
dominant-negative spen transgene that truncates the
carboxy-terminal ~1500 amino acids, including the highly
conserved SPOC domain. When transfected into S2 cul-
tured cells, this construct (Spen∆C) was expressed at high
levels and localized to the nucleus just as we had found for
the endogenous wild-type Spen protein (data not shown).
Ubiquitous expression of Spen∆C was unable to rescue
the lethality or phenotypes associated with spen mutants,
implying an essential function for the conserved carboxy-
terminal SPOC domain. To determine whether Spen∆C
might behave as a dominant-negative mutation, the
Slit–Gal4 driver was used to induce high levels of expres-
sion specifically in the MGCs. MGC-specific expression
of Spen∆C resulted in completely penetrant lethality
(Figure 3; see Supplementary material for additional dis-
cussion). In contrast, and consistent with the lack of
primary neuronal defects associated with spen mutants,
pan-neural expression of Spen∆C using the Elav–Gal4
driver did not compromise the viability or patterning of
the fly. To test the hypothesis that the Slit–Gal4/Spen∆C
lethality might be due to compromised RTK/Ras pathway
signaling, we determined whether increasing the level of
DER/Ras pathway signaling, specifically in the MGCs,
could compensate for the reduction in spen function asso-
ciated with expression of the dominant-negative Spen∆C
transgene. Whereas Slit–Gal4-driven expression of either
an activated RasV12 or the Spen∆C transgene resulted in
lethality, flies expressing both RasV12 and Spen∆C in the
MGCs were viable and appeared normally patterned. The
mutual suppression was extremely penetrant as over 50%
of the expected class of flies was recovered (Figure 3).
Similar, but less penetrant, rescue was obtained when
Spen∆C and a secreted form of the DER ligand Spitz
were coexpressed in the MGCs. Together, these results
strongly suggest that spen functions autonomously in the
MGCs, acting either downstream of or in parallel to Ras as
a positive effector or regulator of RTK signaling. 
Although the molecular mechanisms underlying Spen
function in the RTK/Ras pathway remain to be elucidated,
given its membership of the RRM family [5–7], one possi-
bility is that Spen might directly regulate the processing
and/or stability of specific transcripts to generate function-
ally distinct protein isoforms in response to, or required
for, Ras signaling events. Post-transcriptional regulation of
gene expression allows quick responses to external or
developmental signals, and RRM family members have
been shown to mediate many different cellular processes
including mRNA splicing, stabilization, localization and
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Table 2
The spen gene interacts synergistically with pointed.
Percentage of embryos
Genotypes with axon guidance defects n
spenAH393 (M)/ + (P) 4.2 ± 3.1 101
pntA0435/+ 0 95
spenAH393 (M)/ + (P); pntA0435/+ 23.8 ± 2.2 145
The axon guidance defects were detected by staining with anti-Fas II
antibody. Only stage 15–17 embryos were examined and counted. n,
number of embryos counted. M, maternal; P, paternal.
Figure 3
Increased DER signaling in the midline glia suppresses the lethality
associated with overexpression of the putative dominant-negative
Spen∆C construct. Spen∆C, RasV12 and secreted-Spitz (Sspi) were
expressed as UAS transgenes under control of the MGC-specific
Slit–Gal4 driver. The survival rate was calculated from the ratio of the
actual number of adult flies recovered and the expected number of
flies of each particular genotype. At least 100 flies were counted in
each experiment.
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transport [10]. Two attractive potential targets of such
activity in the CNS are the Ras pathway effector pointed
and the zinc finger transcription factor tramtrack. Both
genes produce alternatively spliced transcripts and are
required in the MGCs [11–13]. The synergistic interac-
tions we have detected between spen and pointed make
pointed a particularly appealing candidate. A third possibil-
ity, given that we isolated spen as an enhancer of an acti-
vated yan allele, is that Spen might function to destabilize
yan transcripts in response to RTK-initiated signals. In this
model, spen would contribute a second level of post-trans-
lational regulation that would reinforce the transient
mitogen-activated protein (MAP) kinase signal that down-
regulates Yan protein, thereby stabilizing release from the
Yan-mediated block to differentiation. In all these scenar-
ios, spen could either function in parallel to the Ras/MAP
kinase cascade, or could itself be directly regulated or 
activated by the pathway. 
Supplementary material
Additional methodological detail and discussion, and figures showing
that Spen∆C functions as a dominant-negative mutant in vivo, Spen
protein is strongly expressed in MGCs, and that there are equal
numbers of cells that are positive for Slit–lacZ and for the marker
Single-minded in spen mutants, are available at http://current-
biology.com/supmat/supmatin.htm.
Acknowledgements
We thank S. Crews, C. Goodman and S. Artavanis-Tsakonas for providing
antibodies; E. Kwan and G. Rubin for help in producing the Spen monoclonal
antibody; T. Laverty for fly stocks; A. Bergmann for fly stocks and helpful dis-
cussions; and J. Yang for teaching us to dissect embryos. The confocal work
was conducted using the W.M. Keck Foundation Biological Imaging Facility at
the Whitehead Institute with the help of R. Fehon and N. Watson. This manu-
script was greatly improved by comments from P. Garrity, T. Orr-Weaver and
M. Voas. I.R. is a recipient of a Burroughs Wellcome Fund Career Award in
the Biomedical Sciences and is a Rita Allen Foundation Scholar. This work
was supported in part by National Institutes of Health Grant EY-12549 to I.R.
References
1. Klambt C, Jacobs JR, Goodman CS: The midline of the Drosophila
central nervous system: a model for the genetic analysis of cell
fate, cell migration, and growth cone guidance. Cell 1991,
64:801-815.
2. Seeger M, Tear G, Ferres-Marco D, Goodman CS: Mutations
affecting growth cone guidance in Drosophila: genes necessary
for guidance toward or away from the midline. Neuron 1993,
10:409-426.
3. Hummel T, Menne T, Scholz H, Granderath S, Giesen K, Klambt C:
CNS midline development in Drosophila. Persp Dev Neurobiol
1997, 4:357-368.
4. Stemerdink C, Jacobs JR: Argos and Spitz group genes function to
regulate midline glial cell number in Drosophila embryos.
Development 1997, 124:3787-3796.
5. Rebay I, Chen F, Hsiao F, Kolodziej PA, Kuang BH, Laverty T, et al.:
A genetic screen for novel components of the Ras/mitogen-
activated protein kinase signaling pathway that interact with the
yan gene of Drosophila identifies split ends, a new RNA
recognition motif-containing protein. Genetics 2000, 154:695-712.
6. Wiellette EL, Harding KW, Mace KA, Ronshaugen MR, Wang FY,
McGinnis W: spen encodes an RNP motif protein that interacts
with Hox pathways to repress the development of head-like
sclerites in the Drosophila trunk. Development 1999,
126:5373-5385.
7. Kuang B, Wu S, Shin Y, Luo L, Kolodziej P: split ends encodes a
large nuclear protein that regulates neuronal cell fate and axon
extension in the Drosophila embryo. Development 2000,
127:1517-1529.
8. Chou TB, Perrimon N: The autosomal FLP-DFS technique for
generating germline mosaics in Drosophila melanogaster.
Genetics 1996, 144:1673-1679.
9. Rothberg JM, Jacobs JR, Goodman CS, Artavanis-Tsakonas S: Slit:
an extracellular protein necessary for development of midline glia
and commissural axon pathways contains both EGF and LRR
domains. Genes Dev 1990, 4:2169-2187.
10. Siomi H, Dreyfuss G: RNA-binding proteins as regulators of gene
expression. Curr Opin Genet Dev 1997, 7:345-353.
11. Klambt C: The Drosophila gene pointed encodes two ETS-like
proteins which are involved in the development of the midline
glial cells. Development 1993, 117:163-176.
12. Read D, Manley JL: Alternatively spliced transcripts of the
Drosophila tramtrack gene encode zinc finger proteins with
distinct DNA binding specificities. EMBO J 1992, 11:1035-1044.
13. Giesen K, Hummel T, Stollewerk A, Harrison S, Travers A, Klambt C:
Glial development in the Drosophila CNS requires concomitant
activation of glial and repression of neuronal differentiation
genes. Development 1997, 124:2307-2316.
946 Current Biology Vol 10 No 15
split ends, a new component of the Drosophila EGF receptor
pathway, regulates development of midline glial cells
Fangli Chen and Ilaria Rebay
Current Biology 21 July 2000, 10:943–946
S1
Supplementary results and discussion
MGC-specific overexpression of Spen∆C resulted in com-
pletely penetrant lethality. The prediction is that, if
Spen∆C acts as a dominant-negative mutant, then overex-
pression of the transgene should result in defects in the
MGCs similar to those seen in spen mutants. To address
this question, the phenotypes associated with Spen∆C
overexpression were examined. Overexpression of
Spen∆C specifically in the MGCs caused ~50% embry-
onic lethality. The remaining animals died at later stages,
with at least some dying late during pupariation. None
were able to eclose. Anti-FasII antibody staining of these
embryos did not reveal any obvious defects in the 
CNS (data not shown). We reasoned that the lack of
CNS defects associated with Spen∆C expression might be 
due to high levels of endogenous Spen. To test this
hypothesis, Spen∆C was overexpressed in the spen zygotic
null mutant background; spen zygotic null mutants 
were embryonic lethal but lacked major CNS defects
because of the heavy maternal contribution (Figure S1a).
Overexpression of Spen∆C in the spen zygotic null back-
ground caused severe CNS defects very similar to those
seen in spen maternal and zygotic nulls (Figure S1b).
Thus, Spen∆C appears to function as a dominant-negative
mutant in vivo.
To confirm that Spen was expressed in the MGCs at the
time when the initial defects were detected, spen mutants
were double labeled with anti-Spen antibody and an
MGC-specific enhancer trap line AA142. The strongest
Spen expression was observed in the MGCs (Figure S2). 
Using the Slit–lacZ enhancer trap line to count the
number of MGCs in spen versus wild-type embryos, we
found no significant difference in number in stage 12/13
embryos. At these stages, the primary defect associated
Supplementary material
Figure S1
Spen∆C functions as a dominant-negative mutant in vivo. Stage 16
embryos labeled with anti-FasII antibody. (a) spenXFM911 zygotic null
embryos appeared phenotypically normal. (b) MGC-specific
overexpression of Spen∆C in the spenXFM911 zygotic null background
resulted in severe axon guidance defects.
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Figure S2
Spen protein is strongly expressed in the midline glial cells. A stage 13
AA142 enhancer trap embryo double labeled with anti-Spen (red) and
anti-β-galactosidase (green) antibodies. (a) Spen expression was
strongest in the MGCs. (b) Anti-β-galactosidase staining marked the
MGCs. (c) The merged images showed almost perfect overlap (yellow).
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with spen mutants appeared to be aberrant MGC migra-
tion. This defect manifested itself as a failure of the
MGCs to migrate anteroposteriorly in a tightly packed
configuration along the dorsal surface of the ventral nerve
cord. Instead, the MGCs in spen mutants migrated more
laterally and became spread out in a scattered and disorga-
nized pattern along the ventral nerve cord (Figure S3).
The migration defect gave the initial appearance that
there may be more MGCs in spen mutants than in the wild
type; careful counting of the Slit–lacZ-positive nuclei sug-
gested that this was not the case, however. Nevertheless,
by stage 17, the number of MGCs was significantly
reduced in spen mutants relative to the wild type. To
make sure that our analyses were not somehow biased by
using only Slit–lacZ to mark the MGCs, we examined
expression of another MGC marker, Single-minded (Sim)
[S1]. Double labeling experiments revealed an almost
precise overlap of the Sim and Slit markers in both the
wild type (data not shown) and in spen mutants (Figure
S3). Specifically, at stage 13, there was no indication of
Sim-positive MGCs that did not also express Slit–lacZ. By
stage 17, both markers revealed a reduction in MGC
number in spen mutants relative to wild type (data not
shown). Thus, it appears that, in spen mutants, normal
numbers of MGCs are initially specified, but later migrate
aberrantly, thereby compromising their ability either to
survive or to maintain the MGC fate.
Supplementary materials and methods
Maternal germline spen/spen clones were generated using the
FLP/FRT system as described by Chou and Perrimon [S2]; lacZ-
expressing balancer chromosomes were used to allow accurate geno-
typing of the collected embryos. Embryos staining was according to
[S3]. Antibodies were used at the following dilutions: anti-Elav at 1:50;
anti-Slit at 1:50; rabbit anti-β-galactosidase (Jackson Laboratory) at
1:20,000; mouse anti-β-galactosidase (Promega) at 1:1000. To gener-
ate antibodies specific to Spen, a GST–Spen fusion protein was
created by subcloning a PCR-amplified fragment (primers: 5′-AGCTA-
GAACTCGAGGATTGG-3′ and 5′-TCCCATCAGACAAGCTCGGC-
3′). This fusion protein was purified as described [S3] and injected into
mice. Monoclonal antibodies were made following standard protocols
[S4]. Spen monoclonal antibody IR25 was used at 1:500.
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Figure S3
There are equal numbers of Sim-positive and Slit–lacZ-positive cells in
spen mutants. A stage 13 spen embryo expressing the Slit–lacZ
MGC-specific enhancer trap double labeled with anti-Sim (red) and
anti-β-galactosidase (green) antibodies. (a) Anti-β-galactosidase
staining highlighted the MGCs expressing the Slit–lacZ enhancer trap.
(b) Anti-Sim staining of the same embryo highlighted the same
population of MGCs. (c) The merge images showed almost perfect
overlap (yellow).
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